Dr. Wolfgang Brysch was chairman of the Board of Directors and Chief Scientific Officer of MetrioPharm AG. From 2016 to 2021, he held the position of Chief Executive Officer (CEO) at MetrioPharm AG. Since October 2021, he has assumed the role of Chief Scientific Officer, and in this position leads the company's scientific research. Until 2014, he was managing director of BioMedion - a successful IT company, specialising in the pharmaceutical industry. Prior to this, he worked as managing director and Chief Scientific Officer at Biognostik GmbH. At that time, Dr. Brysch was also responsible for the preclinical development of various antisense cancer drugs at Antisense Pharma. Until 1992, Dr. Brysch headed a research group for molecular neurobiology and cancer research at the Max-PlanckInstitute Göttingen.